

Results of 2017 Annual General Meeting

16 November 2017

Anteo Diagnostics Limited (ASX: ADO) advises all resolutions except for resolution 2 where passed at the 2017 Annual General Meeting.

The board would like to thank Mr Alan Studley for his service during his tenure.

Further information, required by Section 251AA(2) of the Corporations Act 2001 (Cth), is attached.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

DISCLOSURE OF MEETING PROXY VOTES

Annual General Meeting-Thursdays, 16 November 2017

| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes in respect of which appointment specifies | | | | Poll Results (if applicable) | | |
|---|--|--|---|-------------------------|------------------------|------------|------------------------------|-------------------------|-----------|
| | | | FOR | AGAINST | PROXY'S DISCRETION | ABSTAIN | FOR | AGAINST | ABSTAIN |
| 1. Adoption of Directors' Remuneration Report | S | 442,865,720 | 287,494,265 (64.92%) | 98,089,619 (22.15%) | 57,281,836 (12.93%) | 16,415,599 | n/a | n/a | n/a |
| 2. Re-Election of Director (Mr Alan Studley) | P | 491,514,370 | 152,053,093 (30.94%) | 328,759,182 (66.88%) | 10,702,095 (2.18%) | 2,930,322 | 171,645,756 (34.27%) | 329,259,182 (65.73%) | 3,730,322 |
| 3. Re-Election of Director (Dr Geoff Cumming) | S | 494,370,243 | 442,257,881 (89.46%) | 46,018,091 (9.31%) | 6,094,271 (1.23%) | 74,449 | n/a | n/a | n/a |
| 4. Issues of Securities under Executive/Employee Share Plan | S | 457,596,658 | 369,810,577 (80.82%) | 80,498,298 (17.59%) | 7,287,783 (1.59%) | 3,684,661 | n/a | n/a | n/a |
| 5. Re-Election of Director (Mr Matthew Sanderson) | S | 473,298,200 | 407,157,922 (86.03%) | 47,674,166 (10.07%) | 18,466,112 (3.90%) | 52,000 | n/a | n/a | n/a |